EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
Sponsored by M.D. Anderson Cancer Center
About this study
This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.
Primary Objective: To determine the 3- year DMFS rate of radiotherapy as adjuvant monotherapy for early stage, low risk breast cancers in patients aged ≥ 60 years Secondary Objectives: 1. To determine the HRQoL of patients ≥ 60 years with early stage, low risk breast cancer receiving adjuvant monotherapy with radiotherapy 2. To determine the 3-year and 5-year risk of ipsilateral breast tumor recurrence (IBTR) for early-stage breast cancers treated with lumpectomy and adjuvant radiotherapy without endocrine therapy 3. To quantify the 3-year and 5-year rates of local-regional recurrence, contralateral breast cancer, breast cancer-specific survival and overall survival and the 5 year rate of DMFS 4. To determine the 5-year utilization of salvage mastectomy and other salvage therapies 5. To…
Where this study is enrolling
- I'm interested
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Who can participate
Inclusion criteria
- ✓1. Diagnosis of pathologically-confirmed invasive breast cancer
- ✓2. Age ≥ 60 years
- ✓3. Treatment with breast conserving surgery
- ✓4. Pathologic T stage of T1 or T2 with total tumor size ≤ 3cm including any component of DCIS that may exist in conjunction with invasive disease
- ✓5. Ki-67 . 20% and/or Oncotype 0-10 (Ultra Low)
- ✓6. Final surgical margins negative, defined as no tumor on ink. Lobular carcinoma in situ involving the final surgical margin will be disregarded.
- ✓7. Tumor must be estrogen receptor positive, progesterone receptor positive and HER2Neu non-amplified as per current College of American Pathologists guidelines
- ✓8. Clinical nodal stage cN0
- ✓9. If pathologic nodal staging is obtained, then pN0 or pN0(i+)
- ✓10. Patients have had or have a scheduled discussion with a breast medical oncologist regarding adjuvant treatment options
- ✓11. Patients who have met criteria 4.1.1-4.1.9 who never initiate endocrine therapy OR who initiate adjuvant endocrine therapy but discontinue it within 6 months of initiation \* In some clinical scenarios, patients may have a particularly small volume of tumor, making it not be feasible for all of these biomarkers to be evaluated. In this scenario, if the PI and/or Protocol Collaborators are able to document that a patient is being treated as if they have luminal A (biologically favorable) breast cancer then the patient is eligible for enrollment if all other eligibility criteria are met.
Exclusion criteria
- ✕1. Node positive disease (N1-3)
- ✕2. Metastatic disease (M1)
- ✕3. Grade 3 disease and lymphovascular space invasion in the tumor
- ✕4. Synchronous bilateral breast cancer
- ✕5. Receipt of neoadjuvant therapy
- ✕6. Diagnosis of a collagen vascular disease associated with an increased incidence of radiation toxicities such as scleroderma or systemic lupus erythematosis
- ✕7. Diagnosis of other cancer within the prior 5 years, excluding basal or squamous cell carcinoma of the skin that has been treated
- ✕8. Patient with psychiatric illness/social situations that would limit compliance with study requirements
- ✕9. Prior radiotherapy to the index breast or recurrent cancer of the breast
- ✕10. Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.